# ProQR Therapeutics

the Axiomer platform uses ADAR-recruiting editing oligonucleotides (EONs); AX-0810, a GalNAc-conjugated EON modulating NTCP for cholestatic liver disease, produced the first clinical validation of the platform in 2026 — a dose-dependent up to 8-fold rise in total bile acids at 6 mg/kg (above the 2-fold target-engagemen…

Source: https://en.bioecon.ru/companies/proqr/
Updated: 2026-08-15

- Country: Netherlands
- Ticker: NASDAQ:PRQR

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $59.2 million raised in June 2026 through an underwritten registered direct offering and a concurrent private placement with Eli Lilly and Company | https://www.proqr.com/press-releases/proqr-announces-second-quarter-2026-operating-and-financial-results |
| Headcount | 186 employees on average for 2025 | https://www.proqr.com/files/2026-03/Annual-Report-2025.pdf, https://www.proqr.com/press-releases/proqr-announces-second-quarter-2026-operating-and-financial-results |
| Revenue | €15,906,000 in net revenue for the full year 2025; €10,792,000 in net revenue for the first six months of 2026 | https://www.proqr.com/files/2026-03/Annual-Report-2025.pdf, https://www.proqr.com/press-releases/proqr-announces-second-quarter-2026-operating-and-financial-results |
| Production site | Headquarters and laboratory facilities are located at Zernikedreef 9, Leiden, the Netherlands | https://www.sec.gov/Archives/edgar/data/1612940/000110465926058981/prqr-20260331xex99d1.htm |
| Regulatory approval | Clinical Trial Application (CTA) for Phase 1 study of AX-0810 authorized in Europe (October 2025) | https://proqr.gcs-web.com/static-files/01f6fec3-10b4-4595-8516-2ad9e90cba2d, https://www.proqr.com/files/2026-04/ProQR-Investor-and-Analyst-Event-Beyond-AX-0810-2026_Presentation_to-Post.pdf |

Independent sources: sec.gov

## Technologies

- [RNA editing (ADAR) therapeutics](https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/)